South Korea Ventricular Tachycardia Market Size, Share, Growth, and Industry Analysis, By Diagnostic Techniques     (Electrocardiogram, Continuous ambulatory, Intra-cardiac electrophysiology study, Loop recorder), By Treatment     (Emergency treatment, Cardiopulmonary resuscitation, Electric defibrillation , Anti-arrhythmic medication ) and Forecast, 2026-2034

South Korea Ventricular Tachycardia Market Trends

Digital Monitoring and Precision Electrophysiology Accelerate Clinical Adoption

Continuous rhythm surveillance is shifting from episodic testing toward longer-duration, digitally supported monitoring. A 2026 research benchmark demonstrated multi-lead cardiac reconstruction using a lightweight 364,000-parameter model across 17 subjects, while a separate AI-based intracardiac imaging study used data from 851 subjects and achieved an average positional error of 9.48 mm. These developments illustrate the expanding technological foundation for automated ECG interpretation and precision electrophysiology.

Ablation technology is simultaneously moving toward advanced 3D mapping and non-thermal energy platforms. Boston Scientific's FARAPULSE system became Korea's first MFDS-approved pulsed-field ablation platform in 2024, while next-generation FARAWAVE NAV and FARAVIEW technologies subsequently added real-time 3D visualization. Globally, FARAPULSE had been used in more than 500,000 patients by 2026, demonstrating the scale at which advanced electrophysiology platforms can progress from specialized technology to routine rhythm-management infrastructure.

South Korea Ventricular Tachycardia Market Drivers

Rising Requirement for Rapid Diagnosis and Definitive Rhythm Control

Clinical urgency remains the primary demand driver because sustained ventricular tachycardia can require immediate electrical or pharmacological intervention. Contemporary evidence also strengthens the role of definitive therapy: a 2025 meta-analysis of randomized trials reported a survival benefit when ventricular tachycardia ablation studies were pooled. In another 32-patient study, 29 patients underwent combined endocardial/epicardial mapping and post-procedure VT-free survival reached 71.9% after multiple procedures. These clinical outcomes reinforce investment in ECG, electrophysiology mapping, ICD therapy, defibrillation, and ablation infrastructure.

South Korea Ventricular Tachycardia Market Restraints

Procedure Complexity and Heterogeneous Outcomes Limit Uniform Treatment Expansion

Complex substrates remain difficult to map and eliminate. In a 2025 HCM-VT cohort of 32 patients, 25 scar-mediated re-entry circuits were identified among 28 induced ventricular tachycardias, while index-procedure VT-free survival varied from 83.3% in apical-aneurysm cases to 0% in superior-basal-region and septal cases. Such variability increases dependence on experienced electrophysiologists, repeat procedures, sophisticated mapping, and careful patient selection, restraining uniform adoption despite technological progress.

South Korea Ventricular Tachycardia Market Opportunities

Non-Invasive and AI-Assisted Arrhythmia Management Opens New Clinical Pathways

Technology development is expanding beyond conventional catheter workflows. A systematic review of stereotactic arrhythmia radioablation incorporated 80 studies, including 6 clinical trials, and estimated a 75% reduction in VT burden at 6 months, although 12-month pooled mortality remained 32%. Separately, AI localization research using 334 ventricular-arrhythmia patients reported 94% accuracy, 97% sensitivity and 95% precision. These technologies could expand options for refractory patients and improve pre-procedural localization.

Challenges in South Korea Ventricular Tachycardia Market

Balancing Innovation, Safety and Specialist Workflow Requirements

The principal challenge is converting advanced technology into reproducible outcomes across different cardiac substrates. STAR evidence showed grade 3+ acute toxicities of approximately 7% and substantial heterogeneity, with I² reaching 98.8% for VT-burden reduction. Meanwhile, advanced AI-assisted ICE localization reported 9.48 mm average positional error despite training on 851 subjects. These figures demonstrate that new diagnostic and therapeutic platforms still require validation, workflow standardization and specialist oversight before widespread ventricular-tachycardia deployment.

South Korea Ventricular Tachycardia Market Segmentation

The market is segmented by diagnostic techniques, treatment, disease type and end user. Diagnostic expenditure is led by ECG at approximately 42.70% of 2026 revenue, while continuous ambulatory monitoring represents approximately 27.73%. In treatment, emergency treatment accounts for approximately 26.46%, followed by cardiopulmonary resuscitation at approximately 17.11%.

By Diagnostic Techniques

Electrocardiogram is the largest diagnostic subsegment, increasing from USD 60.51 million in 2025 to USD 63.86 million in 2026 and USD 98.22 million by 2034, representing a 5.53% CAGR. Its approximately 42.70% contribution in 2026 reflects ECG's central role in initial rhythm identification.

Continuous ambulatory monitoring is the fastest-growing diagnostic subsegment, recording a 5.76% CAGR through 2034. It rises from USD 41.47 million in 2026 to USD 64.91 million by 2034, while intra-cardiac electrophysiology studies reach USD 43.64 million and loop recorders USD 24.70 million.

By Treatment

Emergency treatment leads the treatment category at USD 39.56 million in 2026 and is projected to reach USD 61.08 million by 2034 at a 5.58% CAGR. Cardiopulmonary resuscitation follows at USD 25.58 million in 2026, while electric defibrillation generates USD 18.06 million.

Long-term treatment is the fastest-growing treatment subsegment at a 5.89% CAGR, expanding from USD 12.44 million in 2026 to USD 19.67 million in 2034. Implantable cardioverter defibrillators follow closely at 5.86% CAGR, while catheter ablation records 5.61%.

By Disease Type

Non-ischemic and ischemic ventricular tachycardia constitute the disease-type segmentation. No separate monetary values or CAGR figures for these two categories were supplied in the mandatory dataset; therefore, no unsupported subsegment valuation is assigned.

Both categories contribute to the national USD 149.55 million diagnostic opportunity in 2026 and require differentiated mapping, medication, ICD and ablation strategies depending on structural disease and arrhythmogenic substrate.

By End User

Hospitals, ambulatory surgical centres and specialty clinics constitute the end-user structure. Hospitals are the principal setting for emergency defibrillation, electrophysiology studies, complex ablation and ICD implantation; however, the supplied dataset does not provide an independent end-user CAGR or monetary split.

Across end users, the addressable national diagnostic total advances from USD 149.55 million in 2026 to USD 231.47 million in 2034, while treatment expenditure moves from USD 149.51 million to USD 230.99 million.

South Korea Ventricular Tachycardia Market Counties Outlook

South Korea accounts for 100% of the geographic scope of this report. No province- or metropolitan-city-level revenue allocation was supplied; consequently, Seoul, Busan, Incheon, Daegu, Daejeon, Gwangju and other administrative areas are not assigned fabricated shares. National diagnostic expenditure totals USD 149.55 million in 2026, with ECG contributing 42.70% and ambulatory monitoring 27.73%.

At country level, diagnostic revenue reaches USD 231.47 million in 2034, while the treatment total reaches USD 230.99 million. Production-volume data by Korean province were not supplied; the sector split therefore remains anchored to the mandatory national dataset rather than unsupported regional production estimates.

Top players in South Korea Ventricular Tachycardia Market

1. Medtronic plc
2. Boston Scientific Corporation
3. Abbott Laboratories
4. Johnson & Johnson MedTech
5. BIOTRONIK
6. GE HealthCare
7. Philips
8. Siemens Healthineers
9. Nihon Kohden Corporation
10. MicroPort Scientific Corporation
11. ZOLL Medical Corporation
12. AliveCor, Inc.

Top Two Companies

• Medtronic plc

Medtronic maintains a broad rhythm-management position spanning implantable cardiac devices, monitoring and associated digital technologies. In South Korea, the company launched Micra VR2 and AV2 in 2026 with estimated battery longevity of 16–17 years and approximately 40% improvement versus the previous generation; the company stated that more than 80% of eligible patients could potentially be treated with a single device over their lifetime. A specific company percentage of South Korean ventricular-tachycardia revenue is not publicly disclosed and is therefore not fabricated.

• Boston Scientific Corporation

Boston Scientific holds a prominent electrophysiology and cardiac-rhythm-management position, strengthened by Korea's first MFDS approval for a PFA system in 2024. By 2026, FARAPULSE had been used in more than 500,000 patients worldwide, while Korean approval of FARAWAVE NAV and FARAVIEW added 3D mapping functionality. A verified percentage share specifically attributable to South Korean ventricular-tachycardia revenue is not publicly disclosed; accordingly, no unsupported company-share percentage is assigned.

Recent Developments in South Korea Ventricular Tachycardia Market

• 2026:Medtronic announced the South Korean launch of Micra VR2 and AV2, featuring 16–17-year projected battery longevity and approximately 40% longer battery life than the preceding generation.
• 2026:Boston Scientific reported Korean reimbursement-related progress for FARAPULSE; the platform had already treated more than 500,000 patients worldwide.
• 2025:Boston Scientific received Korean regulatory approval for FARAWAVE NAV and FARAVIEW, enabling real-time 3D mapping with its PFA platform.
• 2025:Johnson & Johnson presented Asia-Pacific clinical and real-world evidence for its integrated VARIPULSE, TRUPULSE and CARTO 3 platform.

Research Methodology

The study uses 2025 as the base year, 2026 as the current year and 2026–2034 as the forecast period, with 2022–2024 treated as historical years. Mandatory supplied numerical tables constitute the primary basis for market valuation, segment contribution and CAGR calculations. Percentage contributions were calculated directly from supplied 2026 totals; for example, USD 63.86 million divided by USD 149.55 million produces an ECG contribution of approximately 42.70%. External clinical and corporate sources were used only to contextualize technology, competition and developments, while unavailable disease-type, end-user, provincial and company-share values were not fabricated.